|
Characteristic
|
Initial treatment of ETV-Brand
|
|---|
|
Age, years
|
61 (52.5–68.8)
|
|
Male sex, n (%)
|
119/175 (68.0%)
|
|
BMI, kg/m2
|
24.3 (22.2–27)
|
|
Period of ETV-Brand(years)
|
3.2 (2.7–4.3)
|
|
WBC, × 103/μL
|
5.8 (4.4–7.3)
|
|
HB, g/dL
|
13.8 (12.7–14.6)
|
|
Platelet, × 103/μL
|
145 (104–191)
|
|
ALT, U/L
|
24 (18–32)
|
|
AST, U/L
|
29 (24–36)
|
|
Total bilirubin, mg/dL
|
0.8 (0.6–1.1)
|
|
eGFR, mL/min/1.73 m2
|
81.8 (78.8–87.2)
|
|
FIB-4 score
|
2.7 (2.2–3.0)
|
|
HBeAg-positive, n (%)
|
34 (19.4%)
|
|
Detectable HBV DNA level, IU/mL
|
14.0 (12.4–16.5)
|
|
Undetectable HBV DNA, n (%)
|
142/175 (81%)
|
- Data are expressed as n (%) for categorical data and as mean ± standard deviation or median (interquartile range) for continuous data
- ETV-Brand, entecavir-brand drugs; BMI, body mass index; WBC, white blood cell; HB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4; HBeAg, Hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid
